Study of PYX-201 in Solid Tumors

Inclusion Criteria:

1. Male or non-pregnant, non-lactating female participants age ≥18 years.
2. Histologically or cytologically confirmed solid tumors (see details below):

1. For the dose escalation, the following solid tumors are allowed in participants who have developed disease progression through standard therapy and in participants for whom standard of care therapy that prolongs survival is unavailable or unsuitable (according to the Investigator), which include non-small cell lung cancer (NSCLC), locally advanced/metastatic breast cancer including hormone receptor positive (HR+) and negative (HR-) breast cancer, human epidermal growth factor receptor 2 negative (HER2-) and positive (HER2+) breast cancer, triple negative breast cancer (TNBC) head and neck squamous cell carcinomas (HNSCC), ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma (PDAC), soft tissue sarcoma (STS), hepatocellular carcinoma (HCC), and kidney cancer.
2. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
3. Measurable disease according to RECIST Version 1.1.
4. Life expectancy of >3 months, in the opinion of the Investigator.
5. Adequate hematologic, liver and renal function.
6. Available pre-treatment tumor biopsy.

Exclusion Criteria:

1. History of or concurrent invasive malignancy.
2. Brain metasteses that are untreated or require current therapy.
3. Significant cardiovascular disease.
4. Ongoing active infection requiring systemic anti-infective therapy.
5. Known active hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS).
6. Prior solid organ or bone marrow transplantation.
7. Previously received EDB+FN targeting treatments at any time prior to the start of PYX-201 treatment.
8. Grade >1 neuropathy.
9. History of uncontrolled diabetes mellitus.
10. Participants with corneal epithelial disease.